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Objective: Type 2 diabetes mellitus (T2DM) is associated with increased cardiovascular risk. The role of aggressive glycemic control in preventing cardiovascular (CV) events is unclear. A nested case-control study design was used to evaluate the association between average glycosylated hemoglobin (A1C) and CV outcomes.
Research Design and Methods:
Adults with T2DM were identified among members of Kaiser Permanente Southern California. T2DM was identified based on ICD-9 diagnosis codes and either A1C > 7.5% or prescriptions for hypoglycemic agents. Cases were defined based on nonfatal MI, nonfatal stroke, or death due to cardiovascular events during a 3-year window. Four T2DM controls were matched to each case based on age, sex and index date for the corresponding case. A conditional logistic regression model was used to estimate the odds-ratio (OR) of cardiovascular events comparing three patient groups based on average A1C measured in the pre-index period: ≤6 %; >6%-8%; >8%.
Results: 44,628 controls were matched to 11,157 cases. Patients with an average A1C ≤6% were 20% more likely to experience a cardiovascular event than the >6%-8% group (p<0.0001).
Patients with an average A1C > 8% experienced a 16% increase in the likelihood of a cardiovascular event (p<0.0001). We found evidence of statistical interaction with A1C category and LDL level (p= 0.0002), use of cardiovascular medications (p = 0.02), and use of antipsychotics (p = 0.001).
Conclusions:
High-risk patients with T2DM who achieved mean A1C levels of ≤6% or failed to decrease their A1C below 8% are at increased risk for cardiovascular events. ype 2 diabetes mellitus (T2DM) is associated with an increased risk of microvascular complications such as nephropathy, neuropathy, and retinopathy, as well as macrovascular complications including myocardial infarction (MI) and stroke. Diabetic patients with no previous MI have the same risk of an infarction as nondiabetic patients with a previous MI.(1) Cardiovascular (CV) disease complications are the most common cause of mortality in T2DM patients, accounting for 52% of deaths in this population. (2) Tighter glycemic control and lower glycosylated hemoglobin (A1C) levels decrease the risk of microvascular complications. (3) (4) (5) (6) The American Diabetes Association recommends targeting A1C <7%, while the American Association of Clinical Endocrinologists recommends A1C
≤6.5%. (7, 8) Despite these established guidelines, questions remain regarding the ideal A1C target for minimizing cardiovascular events in T2DM. Observational studies suggest a direct association between hyperglycemia and cardiovascular events, while three large randomized clinical trials failed to establish a cardiovascular benefit for intensive glycemic control. (5,6,9-11) The Veterans Affairs Diabetes Trial randomized diabetic subjects to intensive glycemic control (target A1C ≤6.0%) vs. standard treatment (target A1C 8-9%) and found no significant difference between the treatment arms for major cardiovascular events or all-cause mortality. (10) Similarly, the Action in Diabetes and Vascular Disease trial compared a target A1C ≤6.5% with standard of care and found no significant difference in T macrovascular events.(6) Finally, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial compared a target A1C ≤ 6.0% to a target A1C of 7.0-7.9% in the standard arm.(11) The trial was halted early due to a significant increase in all-cause death and cardiovascular death in the intensively treated arm. We investigated whether the increased risk associated with intensive glycemic control found in the ACCORD trial is observed in a managed care population. We define glycemic control as the mean A1C level for each patient measured over 3 years to mimic the average follow-up period in the ACCORD study.
RESEARCH DESIGN AND METHODS
We investigated the relationship between glycemic control and CV events using a nested case-control design. Study Sample. Data were derived from the Southern California Kaiser Permanente (KPSC) Health Plan which contains information on patient demographics, diagnoses, prescriptions, laboratory results, medical and hospital encounters. The KPSC membership includes approximately 3.3 million individuals representing 15% of the underlying population in Southern California.
Membership is largely employer-based (about 5% of the KPSC population is Medicaid eligible, while 11% is Medicare eligible). The racial composition is as follows: 42.9% Non-Hispanic White, 23.2% Hispanic White, 14.4% Black, 9.6% Asian/Pacific Islander, 0.2% American Indian/Alaskan, 9.4% Other, and 0.3% two or more races. Adult patients (≥18 years) with T2DM were identified based on two recorded T2DM diagnoses between January 2002 to December 2007 and either an A1C > 7.5% or a prescription for an oral hypoglycemic or insulin.
Patients with a diagnosis of polycystic ovarian syndrome, gestational diabetes, or serious illnesses including HIV/AIDS, cancer, sickle cell disease, cystic fibrosis, organ transplant, liver failure, or respiratory failure were excluded from the study. Cases were defined using a primary composite endpoint of non-fatal MI, non-fatal stroke, or death due to cardiovascular causes (MI, stroke, heart failure, arrhythmia) between January 2005 and December 2007. The date of the case defining event was listed as the 'Index Date'. Controls without the primary endpoint during the time window were eligible for matching. Each case was matched with four controls based on age and gender. Controls were assigned a pseudoevent date equal to the index date of their matched case. We excluded patients without three years of continuous KPSC membership plus drug benefit prior to their index date, patients whose first T2DM diagnosis occurred after their index date, and patients with no recorded A1C in the observation window. Cases and controls were assigned to A1C categories based on their average A1C measured over the three years prior to their index date.
Sensitivity analyses were performed using median A1C and most recent A1C prior to the index date. The study's A1C categories are consistent with the ACCORD study: ≤6%; >6% to 8% (comparison group); and >8%. A power analysis indicated that 672 casesmatched in a 1:4 ratio to controls-would be necessary to have 90% power to detect an odds-ratio of 1.15 between A1C categories, adopting the 2-sided 0.05 significance level.(12) Statistical Analyses. We compared baseline characteristics between cases and controls using the 2-sided t-test for continuous variables and the chi-squared statistic for categorical variables. A conditional logistic regression model was fitted to estimate the odds-ratio of the primary endpoint in patients with A1C ≤6% and >8%, relative to patients with A1C between >6-8% adjusting for potential confounders. We used a stratified model for statistically significant interaction terms. In a post-hoc analysis, we fitted a separate model for patients on antipsychotics. All analyses were performed using SAS version 9.1. Covariates. We adjusted for a number of laboratory, diagnostic and prescription covariates in the multivariate analysis.
A dichotomous variable was created to indicate if the patient's A1C was measured at least six times during the three-year pre-index period. Variability in pre-index A1C values was defined as the difference between the minimum and maximum A1C, with an absolute difference of 1% considered to be clinically meaningful. (5, 10) Cholesterol levels [LDL and HDL] measured in the year prior to index date were also included as covariates in the analyses. Concurrent diabetic medications were categorized into six commonly prescribed regimens within KPSC: insulin monotherapy, metformin monotherapy, sulfonylurea monotherapy, insulin plus oral medications, other oral medications or combinations, and no diabetes medication. Medication adherence with diabetic drugs was measured using the proportion of days covered (PDC) over the year prior to index.(13) Dichotomous variables were also defined to reflect the use of statins, ACE-inhibitors, angiotensin receptor blockers (ARB's), other antihypertensives, antiplatelets, firstgeneration and second-generation antipsychotics, antiarrhythmics, tricyclic antidepressants, erythropoietin-stimulating agents (ESA's), and beta-agonists. Dichotomous variables were created to reflect cardiovascular events during the three-year pre-index period, including hospitalizations for MI, stroke, heart failure, or arrhythmia. Outpatient cardiovascular diagnoses included hypertension, peripheral vascular disease, or heart failure.
Diagnoses of retinopathy, nephropathy, chronic kidney disease, neuropathy, and prior amputations suggesting microvascular disease were included as covariates.
Finally, severe episodes of hypoglycemia requiring emergency department services or hospitalizations were captured using dichotomous variables.
RESULTS
Study Population. A pool of 254,118 T2DM patients was identified, from which a total of 16,589 cases met the endpoint of nonfatal MI, nonfatal stroke, or death due to CV causes. After matching and applying the exclusion criteria, a total of 44,628 controls matched to 11,157 cases [ Figure 1 ]. Demographic and clinical characteristics for cases and controls are listed in Table 1 . The mean age was 65.5 (SD 10.5 years) and 57% were male. Cases and controls differed significantly in all other characteristics. Cases were twice as likely as controls to use insulin and were less likely to use statins, ACE-inhibitors, or ARB's. Cases were six times more likely to use antipsychotics and ESA's.
Approximately 90% of the population, cases and controls, had a cardiovascular diagnosis. Compared with controls, cases were four times more likely to have had a cardiovascular event in three-year pre-index period and approximately four times more likely to have had a severe episode of hypoglycemia. Cases were also more likely to have preexisting microvascular disease. Finally, the high percentage of betaagonist use reflects the high prevalence of asthma and COPD within the populationboth cases and controls. Primary Analysis. In the unadjusted logistic model, patients with a three-year average A1C ≤ 6% were 18% more likely to experience a cardiovascular event than patients with an average A1C of >6-8% (OR 1.18, 95% CI 1.11-1.25, P < 0.0001). Patients with an average A1C >8% were 31% more likely to have an event (OR 1.31, 95% CI 1.24-1.38, P< 0.0001) than the comparison group. The results of the multivariate analysis are presented in Table 2 . Patients with an average A1C ≤6% were 20% more likely to experience a CV event, and patients with an average A1C >8% experienced a 16% increase in likelihood of a CV event compared to patients with an average A1C between >6-8% after adjusting for potential confounders. Compared to the group with no diabetes medication use, patients using insulin (alone or in combination) experienced a 2.5-fold increased in the risk of a cardiovascular event, while patients treated with sulfonylurea monotherapy and other combinations of oral medications experienced an increased risk of 55%.
Metformin monotherapy was not associated with an excess CV risk. Adherence to diabetes medications conferred a significant protective effect, with each 10% increase in proportion of days covered being associated with a 44% decrease in the risk of a cardiovascular event. Statins, ACE inhibitors and ARB's were associated with a decrease in odds while antipsychotics, ESA's and tricyclic antidepressants were associated with an increased risk of CV events. Complications such as prior amputations, severe hypoglycemia, and history of previous CV events were significantly associated with CV events, as were indicators of microvascular disease (including nephropathy, neuropathy and retinopathy). High LDL (greater than 100 mg/dL) was also significantly associated with CV events, while high HDL (greater than 40 mg/dL) was protective. The stratified analysis evaluating the impact of A1C categories on cardiovascular outcomes within selected populations are presented in Table 3 . For all subgroups, an average A1C >8% was associated with an increased risk of CV events; however, for those with high LDL or those taking CV medications other than ACE-inhibitors and ARB's, an A1C ≤6% was not significantly associated with event risk. The final two groups in Table 3 reflect that the 2,539 patients taking antipsychotics had a different risk profile from those not taking antipsychotics.
For patients taking antipsychotics, an A1C >8% was associated with a 3-fold increased odds of CV events , while A1C ≤6% was not significantly associated with CV events. For those not taking antipsychotics, the risk profile resembled that of the overall study, with both A1C categories showing statistically significant increases in CV risk relative to the >6-8% group. Sensitivity Analysis. Our model was robust to changes in the definition of glycemic control. Defining glycemic categories based on the median A1C yielded similar results where the risk of cardiovascular events in patients with median A1C ≤6% was 21% higher than for patients with a A1C between >6-8%. Patients with median A1C >8% were at 10% increased risk of events. Using the most recent A1C prior to index, patients with A1C ≤6% were 41 % more likely to have an event than those near target, while those with A1C >8% were at a 5% increased odds of a CV event.
CONCLUSIONS
In this study, patients with T2DM who achieved mean A1C levels of ≤6% or who failed to decrease their A1C below 8% over a 3-year period were at increased risk for cardiovascular events compared to patients with mean A1C levels between >6-8%. While treatment effects varied across subgroups with different risk profiles, these sub-group analyses are consistent with the core results. These results are consistent with the ACCORD trial which found a significant increase in all-cause death and cardiovascular death in the intensively treated arm.(11) Our study also lends support to the results of a recent retrospective cohort study by Currie et al, which found a U-shaped association between survival and A1C.(14) In this study, patients with the lowest A1C levels (median 6.4%) were at a 52% increased risk of allcause mortality relative to patients with a median A1C of 7.5%. In addition, patients in the highest A1C group (median A1C 10.5%) were at 79% increased relative risk. However, our results differ from that of the UKPDS 10-year follow-up study, which demonstrated that intensive treatment was associated with a 15% relative risk reduction in MI (RR 0.85, 95% CI 0.74-0.97,
P=0.01).(5)
The characteristics of our patient population are comparable to the ACCORD trial and the study by Currie et al in terms of age and CV risk profile, and less comparable to the UKPDS. Our study sample was largely elderly (mean 65.5 years) whereas the UKPDS recruited younger, newly diagnosed patients (mean 53 years), with less than 8% of the population having a history of cardiovascular disease. By contrast, 90% of our study population had co-morbid hypertension, and approximately 60% had microvascular disease. The ACCORD trial also included patients with previous CV events or multiple CV risk factors. The study by Currie et al included patients with a history of medication escalation, and 63% of the population had a smoking history. These results suggest that in elderly patients with a high cardiovascular risk profile, intensive glycemic control should be initiated with caution. The medication regimens used in the different studies also warrants discussion. In our study, metformin monotherapy was not associated with excess CV risk, while other combinations of oral drugs including sulfonylureas exhibited an increased risk of events. Similarly, in UKPDS, the relative risk reductions for death and MI were greater for patients receiving metformin-based regimens than for those on sulfonylurea-based regimens. In our study, insulin use alone or in combination with oral medications, was associated with a >2.5-fold increased risk of CV events. These findings are consistent with Currie et al which identified a lower survival rate in insulin users compared with oral medication users. (15) The mechanism for the excess risk associated with insulin and sulfonylurea use is not clearly understood; however, it is possible that hypoglycemia plays a role. It has been proposed that hypoglycemia may precipitate cardiac arrhythmias through hypokalemia and sympatho-adrenal activation. (15, 16) In addition, glucose variability has been implicated as a factor in oxidative stress and vascular inflammation. (17) Alternatively, insulin use may reflect more advanced disease. Taking antipsychotics also appeared to confer an increased risk of CV events, primarily driven by the use of first-generation antipsychotics which are associated with cardiac rhythm disturbances and QTc prolongation.(18) To a lesser extent, secondgeneration antipsychotics-associated with weight gain and metabolic disturbances-also contributed to this effect. (19) As expected, our data shows that patients taking antipsychotics differed significantly in all clinical characteristics from those not taking antipsychotics; thus, it is likely that the two subgroups have different risk profiles. The secondary analysis revealed that intensive glycemic control in patients taking antipsychotics was associated with CV events to a lesser extent than in patients not taking antipsychotics. The effect of antipsychotics on CV risk in diabetic patients deserves further investigation. Our study is subject to a number of limitations. First, the pre-index time window was limited to three years. It is possible that any CV benefits of intensive glycemic control may take longer to become apparent, as shown in UKPDS. However, even a shortterm cardiovascular risk associated with average A1C levels less than 6% is a significant finding with clinical implications. Second, the use of conditional logistic regression in our analysis resulted in oddsratios that may overestimate relative risk when the absolute rate of events is high. (20) While the magnitude of risk may be overestimated, the direction of risk associated with intensive glycemic control is valid. Third, the nonrandomized design may subject the results to treatment selection bias; however, the completeness of the KPSC database allowed us to control for multiple potential confounders, including laboratory results and hospitalization data. Still, some key demographic data were missing, including race and socioeconomic status. Additionally, BMI data were not available for 66% of the study population and smoking status data is generally missing. Finally, duration of diabetes was not available, which was an important determinant of risk associated with intensive treatment based on post-hoc analyses of VADT. (21) Our findings suggest that with respect to A1C control, aggressive lowering may not be appropriate for all T2DM patients. While the potential for selection bias precludes us from drawing causal conclusions about the relationship between mean A1C and cardiovascular risk, our findings, together with those of the ACCORD trial and the study by Currie et al, have implications for clinical practice. While uncontrolled hyperglycemia is an established risk factor for microvascular and macrovascular disease, intensive A1C control may not be the best approach for all T2DM patients.
Initiation of intensive glycemic control warrants careful consideration of individual CV risk profiles. For a given individual, aggressive treatment strategies should carefully weigh the benefits of preventing microvascular complications with the risk of precipitating cardiovascular events. Further research is needed to identify the types of patients for whom intensive glycemic control would be most appropriate, as well as selection of appropriate medication regimens.
Ultimately, mitigating cardiovascular risk requires a multifactorial approach -glycemic control coupled with lipid lowering and blood pressure control, as well as lifestyle interventions. (22) Author contributions. DC wrote study design, researched data, ran statistical analyses, wrote manuscript. JM reviewed and contributed to study design and manuscript. FN reviewed and contributed to study design and manuscript, ran statistically analyses, reviewed and edited manuscript. CC reviewed and contributed to study design and manuscript.
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